Cynata Therapeutics Limited (ASX: CYP) - Share Price

- Current share price for CYP : $0.012

Cynata Therapeutics Limited (CYP), an ASX-listed company, is a Company that is engaged in development and commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus.

CYP General Information ⁺

ASX Code	CYP
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	2
CYP Share Price	$0.012
Day High	$0.012
Day Low	$0.011
Last Close	$0.012
CYP Share Price Movement	- ( No change )

Prices as at 16:40, 26 Jun 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Cynata Therapeutics Limited (CYP) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Cynata Therapeutics Limited (CYP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cynata Therapeutics Limited (CYP) price-sensitive announcements

CYP - Reinstatement to Official Quotation

Cynata Therapeutics Limited (ASX: CYP) announced the reinstatement of its securities to of

Cynata Therapeutics Limited (CYP)
19 Jun 2026 | 9:22 AM

CYP - CYP-004 Osteoarthritis Trial Results

Cynata Therapeutics Limited announced the results of the CYP-004 Phase 3 SCUlpTOR trial fo

Cynata Therapeutics Limited (CYP)
19 Jun 2026 | 9:22 AM

CYP - CYP-001 GvHD Trial Primary Evaluation Results

Cynata Therapeutics Limited announced the primary evaluation results of the Phase 2 clinic

Cynata Therapeutics Limited (CYP)
17 Jun 2026 | 12:05 PM

CYP - Suspension from Quotation

On June 16, 2026, Cynata Therapeutics Limited requested a voluntary suspension of its secu

Cynata Therapeutics Limited (CYP)
16 Jun 2026 | 8:53 AM

Cynata Therapeutics Limited (CYP) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	Ceasing to be a substantial holder	23 Jun 2026 3:47PM	$0.016	$0.012	fallen by 25%
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	Investor Webinar	22 Jun 2026 8:19AM	$0.018	$0.012	fallen by 33.33%
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	Reinstatement to Official Quotation	19 Jun 2026 9:22AM	$0.260	$0.012	fallen by 95.38%
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	CYP-004 Osteoarthritis Trial Results	19 Jun 2026 9:22AM	$0.260	$0.012	fallen by 95.38%
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	CYP-001 GvHD Trial Primary Evaluation Results	17 Jun 2026 12:05PM	$0.260	$0.012	fallen by 95.38%
Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID	Health Care	$3	Suspension from Quotation	16 Jun 2026 8:53AM	$0.260	$0.012	fallen by 95.38%

CYP Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$9.39	-$4.60	-15.50%	0.00%	0.0%
2024A	-$9.74	-$5.40	-44.90%	0.00%	0.0%
2023A	-$14.28	-$9.80	159.00%	0.00%	0.0%

CYP Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
CSL Limited (CSL)	$56,344M	0.1108	-0.1296	0.0166	12.6157	14.4937	14.2573	3.79%	3.06%	3.19%
Clinuvel Pharmaceuticals Limited (CUV)	$507M	0.0287	-0.0028	0.1257	13.9972	14.0363	12.4690	0.50%	0.70%	1.53%
Cynata Therapeutics Limited (CYP)	$3M	-0.1550	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mesoblast Limited (MSB)	$2,693M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,321M	-1.3893	0.0000	-0.1304	0.0000	291.9926	335.7602	0.00%	0.00%	0.00%

CYP Directors

Name	Position	Start Date
Dr Kilian Kelly	Chief Executive Officer, Managing Director	1 Jul 2023
Mr Peter Webse	Company Secretary	1 Jan 0001
Dr Paul K Wotton	Non-Executive Director	8 Jun 2016
Ms Janine Rolfe	Non-Executive Director	1 Sep 2022
Dr Darryl Maher	Non-Executive Director	16 Jun 2020
Dr Geoffrey Edward Duncan Brooke	Non-Executive Director, Non-Executive Chairman	20 May 2019

Cynata Therapeutics Limited (CYP) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 Feb 2025	WOTTON, Paul	Exercise	Options	69,767	$0.300	$20,930.100
20 Feb 2025	WOTTON, Paul	Buy	Direct Shares	69,767	$0.300	$20,930.100
23 Jan 2025	BROOKE, Geoffrey	Issued	Indirect Shares	55,555	$0.180	$9,999.900

See all changes in directors' interest & trades for Cynata Therapeutics Limited (CYP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CYP Management

Name	Position
Mathias Kroll	Chief Business Officer
Jolanta Airey	Chief Medical Officer

CYP Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cynata Therapeutics Limited (CYP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
23,588,040 (9.93%)	Phillip Asset Management Ltd
20,967,806 (8.83%)	FIL Limited and the entities

CYP Calendar of Events

Date	Event
25 February 2027	Report (Interim)
09 October 2026	Report (Annual)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us